Morgan Stanley’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,351
| Closed | -$8.08K | – | 7867 |
|
|
2023
Q2 | $8.08K | Buy |
5,351
+1,243
| +30% | +$1.97K | ﹤0.01% | 6883 |
|
|
2023
Q1 | $7.18K | Sell |
4,108
-330
| -7% | -$555 | ﹤0.01% | 6974 |
|
|
2022
Q4 | $8.39K | Sell |
4,438
-39
| -0.9% | -$86 | ﹤0.01% | 6996 |
|
|
2022
Q3 | $9K | Sell |
4,477
-1,183
| -21% | -$4.98K | ﹤0.01% | 7132 |
|
|
2022
Q2 | $25K | Buy |
5,660
+866
| +18% | +$5.65K | ﹤0.01% | 6909 |
|
|
2022
Q1 | $50K | Sell |
4,794
-13,379
| -74% | -$163K | ﹤0.01% | 6709 |
|
|
2021
Q4 | $272K | Buy |
18,173
+14,206
| +358% | +$336K | ﹤0.01% | 5895 |
|
|
2021
Q3 | $118K | Buy |
3,967
+289
| +8% | +$8.16K | ﹤0.01% | 6281 |
|
|
2021
Q2 | $125K | Buy |
3,678
+3,283
| +831% | +$122K | ﹤0.01% | 6252 |
|
|
2021
Q1 | $16K | Sell |
395
-15,412
| -98% | -$958K | ﹤0.01% | 6811 |
|
|
2020
Q4 | $956K | Buy |
15,807
+14,361
| +993% | +$1.56M | ﹤0.01% | 4694 |
|
|
2020
Q3 | $193K | Sell |
1,446
-222
| -13% | -$37.1K | ﹤0.01% | 5140 |
|
|
2020
Q2 | $282K | Buy |
1,668
+327
| +24% | +$54.5K | ﹤0.01% | 4906 |
|
|
2020
Q1 | $193K | Sell |
1,341
-293
| -18% | -$89.6K | ﹤0.01% | 4879 |
|
|
2019
Q4 | $540K | Buy |
1,634
+221
| +16% | +$101K | ﹤0.01% | 4885 |
|
|
2019
Q3 | $707K | Buy |
1,413
+351
| +33% | +$198K | ﹤0.01% | 4495 |
|
|
2019
Q2 | $645K | Buy |
1,062
+368
| +53% | +$226K | ﹤0.01% | 4468 |
|
|
2019
Q1 | $424K | Sell |
694
-66
| -9% | -$36K | ﹤0.01% | 4646 |
|
|
2018
Q4 | $278K | Buy |
760
+4
| +0.5% | +$2.15K | ﹤0.01% | 5142 |
|
|
2018
Q3 | $510K | Buy |
756
+418
| +124% | +$296K | ﹤0.01% | 4988 |
|
|
2018
Q2 | $294K | Buy |
338
+164
| +94% | +$188K | ﹤0.01% | 5385 |
|
|
2018
Q1 | $218K | Buy |
174
+119
| +216% | +$176K | ﹤0.01% | 5434 |
|
|
2017
Q4 | $82K | Sell |
55
-5,005
| -99% | -$7.91M | ﹤0.01% | 5698 |
|
|
2017
Q3 | $10.4M | Buy |
5,060
+5,059
| +505,900% | +$11.9M | ﹤0.01% | 2233 |
|
|
2017
Q2 | $3K | Sell |
1
-13
| -93% | -$33.5K | ﹤0.01% | 6430 |
|
|
2017
Q1 | $43K | Buy |
14
+13
| +1,300% | +$31.6K | ﹤0.01% | 5879 |
|
|
2016
Q4 | $2K | Sell |
1
-1
| -50% | -$1.33K | ﹤0.01% | 6398 |
|
|
2016
Q3 | $3K | Hold |
2
| – | – | ﹤0.01% | 6336 |
|
|
2016
Q2 | $4K | Hold |
2
| – | – | ﹤0.01% | 6271 |
|
|
2016
Q1 | $4K | Buy |
2
+1
| +100% | +$2.15K | ﹤0.01% | 6336 |
|
|
2015
Q4 | $2K | Sell |
1
-1
| -50% | -$2.44K | ﹤0.01% | 6528 |
|
|
2015
Q3 | $4K | Buy |
+2
| New | +$5.3K | ﹤0.01% | 6426 |
|
Morgan Stanley's NBRV Position: Q3 2023 in Review
Morgan Stanley sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2023, closing a stake of 5,351 shares — an estimated $8.08K sold.
Morgan Stanley first reported a position in NBRV in Q3 2015 and held it in 32 quarters. The position peaked at $10.4M in Q3 2017. 0 funds tracked by Wall St. Rank hold NBRV as of Q3 2023.
- Morgan Stanley reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 5,351 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2023, an estimated $8.08K.
- Morgan Stanley first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 32 quarters.
- Morgan Stanley's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $10.4M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.